There is ample evidence now that many CLL patients don't respond well to vaccination against the SARS-COV2 virus. At least, a sizeable fraction don't develop measurable antibodies. From big pharma's point of view, therefore, we are a gap in the market for protection against Covid, and a handful of providers are lining up to fill that gap, including Lilly, Regeneron and Astrazeneca sciencemag.org/news/2021/01... As prophylactics, these drugs are still in clinical trials.
Astrazeneca made prior agreements to supply its long-acting antibody, known as AZD7442, in both the USA and the UK. The US government ordered up to 700,000 doses and the UK government 1 million doses, see bloomberg.com/news/articles...
It seems that Astrazeneca expects to release results of their phase 2/3 trial of AZD7442 by the end of June. But ahead of those results, it is reported that "the U.K. government has rethought plans to buy one million doses" fiercebiotech.com/biotech/a...
This may just be an unfounded rumour of course. But if the UK government were to withdraw its support for AZD7442, and fail to support any protective monoclonal for use by the NHS, it could leave many immunocompromised people, including CLL patients, in the invidious position of needing to shield until Covid is well and truly over.
This is not a message of doom and gloom, just a heads up. We should watch developments and be prepared to launch a concerted campaign if necessary.